Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
100 | 100 | 14,346,686 | 1,616 | The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graf... | 1. A formulation comprising a solid dispersion product comprising
(a) an active agent having at least one of a hydrogen bond donor moiety and a proton donor moiety, (b)a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and (c) a pharmaceutically acceptable pH modifier;... | The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graf... | 1,600 |
101 | 101 | 11,901,875 | 1,643 | A phosphoprotein detection reagent that selectively binds phosphoamino acids. Methods of generating and employing the reagent are also provided, as are methods of detecting modulation of protein phosphorylation are disclosed. Methods of detecting a change in state of a cell are also disclosed. Additionally, a kit for t... | 1. A phosphoprotein detection reagent (PPDR) comprising:
(a) a polydentate chelator that coordinates a Zn2+ ion; and (b) a detectable moiety conjugated to the polydentate chelator, wherein when the Zn2+ ion is coordinated to the chelator, a chelator-metal ion moiety is formed that can selectively bind to a phosphory... | A phosphoprotein detection reagent that selectively binds phosphoamino acids. Methods of generating and employing the reagent are also provided, as are methods of detecting modulation of protein phosphorylation are disclosed. Methods of detecting a change in state of a cell are also disclosed. Additionally, a kit for t... | 1,600 |
102 | 102 | 14,128,379 | 1,641 | The present invention relates to a method for identification of specific target proteins in a protein sample following a detection procedure, such as a Western blotting procedure, wherein the membrane is probed with at least two primary antibodies directed against the same and/or different epitopes of the same target p... | 1. A method for identification of specific target biomolecules in a sample following a detection procedure, wherein a gel or membrane is probed with at least two probes directed against the same and/or different sites of the same target biomolecule, and wherein specific binding to the target biomolecule in a sample is ... | The present invention relates to a method for identification of specific target proteins in a protein sample following a detection procedure, such as a Western blotting procedure, wherein the membrane is probed with at least two primary antibodies directed against the same and/or different epitopes of the same target p... | 1,600 |
103 | 103 | 14,007,520 | 1,628 | The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ, <30 and 15<δ d <22. Use for caring for, making up and cleansing keratin materials. | 1. Composition comprising, in a physiologically acceptable aqueous medium: 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and an organic solvent with solubility parameters in the Hansen solubility space such that 14.5<δa<30 and 15<δd<22. 2. Composition according to the preceding claim, wherein the organic solvent is chosen fr... | The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ, <30 and 15<δ d <22. Use for caring for, making up and cleansing keratin materials.1. Composi... | 1,600 |
104 | 104 | 13,499,503 | 1,613 | The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I):
in which:
R2 represents a hydrogen atom or a methyl or ethyl radical; R3 ... | 1. Use as a preserving agent, in particular in a cosmetic, dermatological, pharmaceutical, nutraceutical or oral cosmetic composition, of at least one compound of formula (I):
in which:
either R2 represents a hydrogen atom and R3 represents a linear C1-C6 alkyl radical (saturated), optionally substituted wit... | The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I):
in which:
R2 represents a hydrogen atom or a methyl or ethyl radical; R3 ... | 1,600 |
105 | 105 | 14,051,164 | 1,653 | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Down... | 1. (canceled) 2. A method to treat inflammation in a subject, the method comprising assessing cells in a preparation of cells for a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce cyt... | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Down... | 1,600 |
106 | 106 | 14,035,811 | 1,644 | Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing r... | 1-12. (canceled) 13. A method of treating a gastrointestinal inflammatory disorder in a patient, the method comprising administering to the patient a therapeutically effective amount of an integrin beta7 antagonist, wherein the integrin beta7 antagonist is administered subcutaneously at a flat dose. 14. The method of c... | Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing r... | 1,600 |
107 | 107 | 14,558,618 | 1,631 | A method of identifying one or more biomarkers associated with one or more drugs effective to stop or repress proliferation of cancer cells, and a system for predicting effectiveness of the same. The method includes statistically analyzing (i) a first dataset of expression levels of proteins or glycoproteins in the can... | 1. A method of identifying one or more of a plurality of drugs effective to stop or repress proliferation of cancer cells, comprising:
statistically analyzing (i) a first dataset of expression levels of a plurality of proteins or glycoproteins in said cancer cells and (ii) a second dataset of responses of said cancer c... | A method of identifying one or more biomarkers associated with one or more drugs effective to stop or repress proliferation of cancer cells, and a system for predicting effectiveness of the same. The method includes statistically analyzing (i) a first dataset of expression levels of proteins or glycoproteins in the can... | 1,600 |
108 | 108 | 13,900,166 | 1,628 | A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG expression in the cancer cells, and comparing the measured levels of UDG expression in the cancer cells to a control level. | 1. A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite that induces or promotes incorporation of a UDG substrate into DNA of cancer cells, comprising:
obtaining a sample of cancer cells from the subject; measuring the level of UDG in the cancer cells; and comparing th... | A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG expression in the cancer cells, and comparing the measured levels of UDG expression in the cancer cells to a control level.1. A... | 1,600 |
109 | 109 | 12,904,049 | 1,628 | The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury. | 1. A method for reducing the risk of pathological effects of traumatic brain injury, comprising:
(a) administering to a subject who is at risk of traumatic brain injury a composition comprising at least about 35 wt % docosahexaenoate (DHA), wherein the composition is administered in a prophylactically effective amount ... | The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury.1. A method for reducing the risk of pathological effects of traumatic brain injury, comprising:
(a) administering to a subject who is at risk of traumatic brain injury a composition comprisi... | 1,600 |
110 | 110 | 15,513,735 | 1,627 | The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challen... | 1. A method of treating porcine epidemic diarrhea virus (PEDV) infection, comprising administering to a nursery pig narasin with an orally-acceptable carrier. 2. The method of claim 1, wherein the orally-acceptable carrier is selected from the group comprising an animal feed, a liquid composition other than an animal f... | The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challen... | 1,600 |
111 | 111 | 11,265,414 | 1,618 | The invention provides methods and compositions for regulating weight and size in animals. | 1. A method for reducing white adipose tissue in an animal comprising administering a high glycine diet comprising about 10% to about 30% glycine to the animal. 2. The method of claim 1, wherein the high glycine diet comprises glycine analogs or a combination of glycine and glycine analogs. 3. A method for inducing apo... | The invention provides methods and compositions for regulating weight and size in animals.1. A method for reducing white adipose tissue in an animal comprising administering a high glycine diet comprising about 10% to about 30% glycine to the animal. 2. The method of claim 1, wherein the high glycine diet comprises gly... | 1,600 |
112 | 112 | 14,980,371 | 1,611 | In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present... | 1. A method of treatment comprising delivering therapeutic-agent releasing microparticles into a feeder artery of a tumor, wherein the microparticles release a first drug over a first time period, wherein the microparticles release a second drug over a second time period, wherein a lag period of substantially no drug r... | In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present... | 1,600 |
113 | 113 | 15,101,267 | 1,656 | The present disclosure relates to recombinantly engineered cells that contain a chlorite dismutase polypeptide and methods for culturing such cells in a culture medium containing chlorite in an amount sufficient to reduce the growth rate or kill contaminating microorganisms without killing the recombinantly engineered ... | 1-49. (canceled) 50. A method of culturing a cell, comprising:
a) culturing a cell recombinantly engineered to express a chlorite dismutase polypeptide in a culture medium under conditions whereby the chlorite dismutase polypeptide is expressed in said cell, wherein said culture medium comprises one or more contaminati... | The present disclosure relates to recombinantly engineered cells that contain a chlorite dismutase polypeptide and methods for culturing such cells in a culture medium containing chlorite in an amount sufficient to reduce the growth rate or kill contaminating microorganisms without killing the recombinantly engineered ... | 1,600 |
114 | 114 | 13,582,177 | 1,611 | The present invention relates to novel granular silicas for use as support material, especially as support for catalysts for fixed bed reactors, and to the production and use thereof. | 1. Granular silica having
an Hg pore volume (<4 μm) of more than 0.90 ml/g, a dQ3=10% of more than 400 μm with, at the same time, a dQ3=90% of less than 3000 μm, and a ratio of the d50 without ultrasound exposure to d50 after 3 min of ultrasound exposure of <4.00, the measurement being effected on a fraction of particl... | The present invention relates to novel granular silicas for use as support material, especially as support for catalysts for fixed bed reactors, and to the production and use thereof.1. Granular silica having
an Hg pore volume (<4 μm) of more than 0.90 ml/g, a dQ3=10% of more than 400 μm with, at the same time, a dQ3=9... | 1,600 |
115 | 115 | 14,770,901 | 1,611 | Described herein are toothpastes comprising a first dentifrice comprising a calcium carbonate abrasive and a second dentifrice comprising a zinc ion source in a gel base, wherein the second dentifrice is entrained as a stripe in the first dentifrice, as well as products comprising the toothpaste and methods of making a... | 1. A toothpaste product comprising
a first dentifrice comprising a calcium carbonate abrasive, a second dentifrice comprising a zinc ion source in a gel base, and a container which holds the first dentifrice physically separate from the second dentifrice until the dentifrices are dispensed. 2. The product of claim 1, w... | Described herein are toothpastes comprising a first dentifrice comprising a calcium carbonate abrasive and a second dentifrice comprising a zinc ion source in a gel base, wherein the second dentifrice is entrained as a stripe in the first dentifrice, as well as products comprising the toothpaste and methods of making a... | 1,600 |
116 | 116 | 15,070,718 | 1,627 | Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematop... | 1. A compound of Formula I:
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,
wherein
X is selected from N or CR4a;
X′ is selected from N or CR4b;
Y is selected from N or CR5a;
Y′ is selected from N or CR5b;
provided at least one of X, X′, Y, and Y′ is N;
R1 is selected from the group c... | Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematop... | 1,600 |
117 | 117 | 14,057,521 | 1,651 | Described herein are enhanced compositions and methods for storing biomaterials. In certain aspects, these biomaterials include natural and engineered eukaryotic tissues. The methods described herein include storing these biomaterials in such a manner that reduces or prevents the loss of biomaterial properties (e.g., e... | 1. A composition comprising a biomaterial placed in a solution that includes at least one agent that reduces or prevents a loss of biomaterial properties, wherein
the solution is an animal product-free solution, the biomaterial comprises chondrocytes in an extracellular matrix or cartilage, and the at least one agent c... | Described herein are enhanced compositions and methods for storing biomaterials. In certain aspects, these biomaterials include natural and engineered eukaryotic tissues. The methods described herein include storing these biomaterials in such a manner that reduces or prevents the loss of biomaterial properties (e.g., e... | 1,600 |
118 | 118 | 13,622,666 | 1,618 | A topical composition includes a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein. The hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point below the melting point of the respective hydrophobic materi... | 1. A topical composition comprising a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein, wherein
the hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point less than the melting point of the respective h... | A topical composition includes a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein. The hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point below the melting point of the respective hydrophobic materi... | 1,600 |
119 | 119 | 14,078,614 | 1,619 | Synthetic composite materials for use, for example, as orthopedic implants are described herein. In one example, a composite material for use as a scaffold includes a thermoplastic polymer forming a porous matrix that has continuous porosity and a plurality of pores. The porosity and the size of the pores are selective... | 1. A porous reinforced composite scaffold material, comprising:
a thermoplastic polymer material having essentially uniform porosity and comprising a plurality of anisometric calcium phosphate particles distributed essentially uniformly throughout, wherein the composite comprises a plurality pores that are defined by v... | Synthetic composite materials for use, for example, as orthopedic implants are described herein. In one example, a composite material for use as a scaffold includes a thermoplastic polymer forming a porous matrix that has continuous porosity and a plurality of pores. The porosity and the size of the pores are selective... | 1,600 |
120 | 120 | 15,183,310 | 1,611 | The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxy... | 1-12. (canceled) 13. A method for promoting and/or accelerating fibroblast proliferation in vivo or ex vivo, comprising: providing a composition comprising an effective amount of a copolymer of a salt of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid and of 2-hydroxyethylpropenoate ester. 14. The method as... | The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxy... | 1,600 |
121 | 121 | 14,438,564 | 1,636 | This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed. | 1. A recombinant replication competent gammaretrovirus comprising:
a retroviral GAG protein; a retroviral POL protein; a retroviral envelope; a retroviral polynucleotide comprising Long-Terminal Repeat (LTR) sequences at the 3′ end of the retroviral polynucleotide sequence, a promoter sequence at the 5′ end of the retr... | This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.1. A recombinant replication competent gammaretrovirus comprising:
a retroviral GAG protein; a retroviral POL protein; a retroviral envelope... | 1,600 |
122 | 122 | 14,391,883 | 1,641 | A rapid assay for detection of human cellular fibronectin (c-Fn) where ELISA-based assays have previously been developed for detecting and measuring cellular fibronectin in biological fluids, but these methods are too time-consuming for practical clinical diagnostic use. The assay of the present invention enables predi... | 1-22. (canceled) 23. A rapid assay for the prediction of bleeding in a human test subject that can determine in 60 minutes or less the level of human cellular fibronectin (c-Fn) in a test sample taken from a subject;
wherein said test sample is drawn from the group consisting of whole blood, serum, or a plasma sample. ... | A rapid assay for detection of human cellular fibronectin (c-Fn) where ELISA-based assays have previously been developed for detecting and measuring cellular fibronectin in biological fluids, but these methods are too time-consuming for practical clinical diagnostic use. The assay of the present invention enables predi... | 1,600 |
123 | 123 | 12,782,616 | 1,634 | Disclosed are methods and systems for determining the three-dimensional structure of chromatin in eukaryotic cells. More specifically, disclosed are methods and systems for obtaining chromatin structural information by surface immobilization, i.e tethering crosslinked protein:DNA complexes and/or ligated DNA complexes ... | 1. A method of determining the three-dimensional arrangement of chromatin in a cell, comprising:
Contacting a cell with a cross-linking reagent to cross-link DNA and protein in the cell such that the structural organization of the chromatin or other protein:DNA complexes is preserved; lysing the cell; producing cross-l... | Disclosed are methods and systems for determining the three-dimensional structure of chromatin in eukaryotic cells. More specifically, disclosed are methods and systems for obtaining chromatin structural information by surface immobilization, i.e tethering crosslinked protein:DNA complexes and/or ligated DNA complexes ... | 1,600 |
124 | 124 | 13,984,373 | 1,639 | The present invention provides: a method for detecting a nucleic acid, which efficiently eliminates non-specific detection of nucleic acids other than the nucleic acid as a detection target, so that detection specificity of the nucleic acid as a detection target can be further improved; or the like. This method for det... | 1. A method for detecting a nucleic acid, comprising:
contacting a plurality of types of gels of different gel concentrations, on which a probe is immobilized, with a reaction solution comprising a nucleic acid that serves as a template for nucleic acid amplification, a primer set for nucleic acid amplification, a nucl... | The present invention provides: a method for detecting a nucleic acid, which efficiently eliminates non-specific detection of nucleic acids other than the nucleic acid as a detection target, so that detection specificity of the nucleic acid as a detection target can be further improved; or the like. This method for det... | 1,600 |
125 | 125 | 14,543,999 | 1,613 | A composition having biocidal properties is disclosed. The composition includes a first biocide, optionally a second biocide, and a biocide enhancing agent. The first biocide may comprise an isothiazolin. The second biocide may comprise a pyrithione. The biocide enhancing agent may comprise an amine, an amine salt, an ... | 1. A composition having biocidal properties comprising:
a first biocide comprising an isothiazolin; a second biocide comprising pyrithione; and a biocide enhancing agent comprising an amine, an amine salt, an amine oxide, or mixtures thereof, the amine, the amine salt, or the amine oxide having a carbon chain length of... | A composition having biocidal properties is disclosed. The composition includes a first biocide, optionally a second biocide, and a biocide enhancing agent. The first biocide may comprise an isothiazolin. The second biocide may comprise a pyrithione. The biocide enhancing agent may comprise an amine, an amine salt, an ... | 1,600 |
126 | 126 | 15,152,739 | 1,627 | Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed ... | 1. A method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. 2. The method of claim 1 with the agent being suspended in the hydrogel. 3. The method of claim 1 with 50% to 100% w/w... | Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed ... | 1,600 |
127 | 127 | 13,941,442 | 1,631 | The present invention is generally directed to a hierarchical genome assembly process for producing high-quality de novo genome assemblies. The method utilizes a single, long-insert, shotgun DNA library in conjunction with Single Molecule, Real-Time (SMRT®) DNA sequencing, and obviates the need for additional sample pr... | 1. A method of identifying a sequence of a nucleic acid, the method comprising:
obtaining a set of reads for the nucleic acid sequence; forming a seed sequence dataset comprising one or more seed reads identified as reads in the set of reads having lengths greater than 1,000 base pairs; aligning each read in the set of... | The present invention is generally directed to a hierarchical genome assembly process for producing high-quality de novo genome assemblies. The method utilizes a single, long-insert, shotgun DNA library in conjunction with Single Molecule, Real-Time (SMRT®) DNA sequencing, and obviates the need for additional sample pr... | 1,600 |
128 | 128 | 14,430,293 | 1,637 | The present invention provides a method for analysis of target nucleic acids which are present in low amounts. In particular, the method comprises the following steps: i. providing a sample wherein target nucleic acids are present in a low amount, ii. generating a reduced representation library of said target nucleic a... | 1. A method for analysis of target nucleic acids, the method comprising:
i. providing a sample wherein target nucleic acids are present in a low amount, ii. generating a reduced representation library of said target nucleic acids by a method comprising:
fragmenting said target nucleic acids;
ligating adaptors to said f... | The present invention provides a method for analysis of target nucleic acids which are present in low amounts. In particular, the method comprises the following steps: i. providing a sample wherein target nucleic acids are present in a low amount, ii. generating a reduced representation library of said target nucleic a... | 1,600 |
129 | 129 | 14,011,552 | 1,627 | Formulations and methods for transdermal drug delivery compositions that include anastrozole are disclosed. Transdermal anastrozole compositions of the present disclosure may be indicated for treating testosterone deficiency. Disclosed transdermal anastrozole compositions may include permeation enhancers that may impro... | 1. A pharmaceutical composition, comprising: anastrozole and at least one permeation enhancer. 2. The pharmaceutical composition of claim 1, wherein the anastrozole comprises about 0.01% to about 0.1% by weight of the pharmaceutical composition. 3. The pharmaceutical composition of claim 1, wherein the permeation enhan... | Formulations and methods for transdermal drug delivery compositions that include anastrozole are disclosed. Transdermal anastrozole compositions of the present disclosure may be indicated for treating testosterone deficiency. Disclosed transdermal anastrozole compositions may include permeation enhancers that may impro... | 1,600 |
130 | 130 | 13,500,784 | 1,654 | The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the se... | 1. A method for treating, limiting and/or preventing muscle atrophy comprising the steps of administering a composition comprising glucagon-like peptide 2 (GLP 2) having a caloric density in the range of 0.8-2.0 kcal/ml with at least 10% of the calories resulting from fat and at least 25% of the calories resulting from... | The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the se... | 1,600 |
131 | 131 | 14,381,370 | 1,617 | The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same. | 1. A pharmaceutical composition for topical delivery of a moisture activated active pharmaceutical ingredient, the composition comprising:
(a) a hydrophobic base; and (b) an amphiphilic compound. 2. The pharmaceutical composition of claim 1, wherein
the hydrophobic base is present in the composition at a concentration ... | The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.1. A pharmaceutical composition for topical delivery of a moisture activated active pharmaceutical ingredient, the composition comprising:
(a) a hydrophobic base; and (b) an amphiphilic compound. ... | 1,600 |
132 | 132 | 13,354,714 | 1,612 | The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route. | 1. A transmuccosal administration system for a pharmaceutical active ingredient comprising 0.01-80% by weight of an active ingredient of the structural formula (I)
wherein R1 is a C1-4 lower alkyl group; R2 is a hydrogen atom or an optional substituted alkyl or an optional substituted alkenyl group; R3 and R... | The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.1. A transmuccosal administration system for a pharmaceutical active ingredient comprising 0.01-80% by weight of an active ingredient of the structural ... | 1,600 |
133 | 133 | 11,055,506 | 1,632 | The present invention relates to an enriched or purified population of dopaminergic neuronal progenitor cells and an enriched or purified population of dopaminergic neurons. These enriched or purified populations are derived from a population of embryonic stem cells by inducing production of dopaminergic neuronal proge... | 1. A method of isolating an enriched or purified population of dopaminergic neuronal progenitor cells from a population of embryonic stem cells comprising:
providing a population of embryonic stem cells; inducing production of dopaminergic neuronal progenitor cells from the population of embryonic stem cells; select... | The present invention relates to an enriched or purified population of dopaminergic neuronal progenitor cells and an enriched or purified population of dopaminergic neurons. These enriched or purified populations are derived from a population of embryonic stem cells by inducing production of dopaminergic neuronal proge... | 1,600 |
134 | 134 | 13,038,641 | 1,629 | The invention relates to the use of osmolytes, for example, ectoine, hydroxyectoine, firoin, firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, 1,3-dimannosyl-di-myo-inositol-phosphate (DMIP) and/or diinositol phosphate and their equally effective derivatives and/or pharmacologically acceptable salts thereof, f... | 1.-10. (canceled) 11. A method of treatment of diseases caused by the effects of suspended particulate on lung tissue and/or the cardiovascular diseases related thereto comprising administering an effective amount of at least one osmolyte selected from ectoine, hydroxyectoine or a pharmacologically compatible salt ther... | The invention relates to the use of osmolytes, for example, ectoine, hydroxyectoine, firoin, firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, 1,3-dimannosyl-di-myo-inositol-phosphate (DMIP) and/or diinositol phosphate and their equally effective derivatives and/or pharmacologically acceptable salts thereof, f... | 1,600 |
135 | 135 | 13,787,480 | 1,612 | Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesic... | 1. A formulation of one or more non-steroidal anti-inflammatory drugs, comprising:
one or more non-steroidal anti-inflammatory drugs; and multivesicular liposomes, wherein the one or more non-steroidal anti-inflammatory drugs are encapsulated in the multivesicular liposomes. 2. The formulation of claim 1, wherein said ... | Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesic... | 1,600 |
136 | 136 | 13,954,285 | 1,615 | The present invention provides a composition containing a pyrithione compound and a pyranone compound and a method of reducing discoloration of compositions containing pyrithione compounds. The composition may be a soap composition. | 1. A method for reducing discoloration of a pyrithione-containing composition due to the presence of an iron ion, said method comprising:
adding a pyranone compound to the pyrithione-containing composition in an amount effective to complex iron ions introduced to the composition from impurities present in raw materials... | The present invention provides a composition containing a pyrithione compound and a pyranone compound and a method of reducing discoloration of compositions containing pyrithione compounds. The composition may be a soap composition.1. A method for reducing discoloration of a pyrithione-containing composition due to the... | 1,600 |
137 | 137 | 13,519,391 | 1,623 | This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix. More specifically, the invention relates to a solid matrix for the storage of purified DNA, which matrix has been treated with a solution comprising plant p... | 1. A solid matrix suitable for the storage of purified DNA which matrix has been treated with a solution comprising inulin. 2. The solid matrix of claim 1, which has also been treated with PEG. 3. The solid matrix of claim 1, wherein the inulin treatment is at a concentration of up to 20%. 4. The solid matrix of claim ... | This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix. More specifically, the invention relates to a solid matrix for the storage of purified DNA, which matrix has been treated with a solution comprising plant p... | 1,600 |
138 | 138 | 14,777,461 | 1,611 | Described herein are oral care compositions comprising a deoxy sugar antimetabolite and methods of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in a subject. | 1. A method of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in the oral cavity of a subject comprising administering to the subject an oral care composition comprising a deoxy sugar antimetabolite with no additional antibacterial agent and an orally acceptable carrier. 2. The method accor... | Described herein are oral care compositions comprising a deoxy sugar antimetabolite and methods of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in a subject.1. A method of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in the oral cavity of a subject comprisin... | 1,600 |
139 | 139 | 12,290,049 | 1,632 | Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the ... | 1. A method of obtaining a population of insulin autoantigen-specific regulatory T cells, the method comprising:
administering to a subject a composition comprising an effective amount of an insulin autoantigen and an oil-in-water adjuvant; obtaining a sample comprising peripheral blood mononuclear cells (PBMCs) from t... | Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the ... | 1,600 |
140 | 140 | 13,757,392 | 1,631 | Embodiments disclosed herein relate to methods and systems for performing an automated assay, and particularly to performing an assay on a plurality of samples on an automated instrument. | 1. A method of performing an automated assay on a plurality of samples, said method comprising:
providing an automated instrument comprising a first workstation and a second workstation, each of said first and second workstations configured to receive and processes a plurality of samples according to a plurality of dif... | Embodiments disclosed herein relate to methods and systems for performing an automated assay, and particularly to performing an assay on a plurality of samples on an automated instrument.1. A method of performing an automated assay on a plurality of samples, said method comprising:
providing an automated instrument com... | 1,600 |
141 | 141 | 15,287,242 | 1,612 | Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same. | 1. An oral care composition comprising:
a first metal salt, having a solubility of greater than 0.001 g/100 mL in water at 20° C.; a second metal salt, having a solubility of 0.001 g/100 mL, or less, in water at 20° C.; and a free water content of greater than about 10%, by weight;
wherein the first metal salt and the... | Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same.1. An oral care composition comprising:
a first metal salt, having a solubility of greater than 0.001 g/100 mL in water at 20° C.; a second metal salt, having a solubility of 0.001 g/100 mL, or less, in... | 1,600 |
142 | 142 | 13,721,744 | 1,612 | The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at le... | 1. A solid pharmaceutical composition comprising a progestogen, an estrogen, a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical acceptable excipient or carrier. 2.-42. (canceled) 43. A process for the manufacture of a composition according to claim 1 comprising the ste... | The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at le... | 1,600 |
143 | 143 | 15,306,830 | 1,632 | We have found a counter-intuitive way to improve the commercial-scale production of recombinant biological products in adherent-cell bioreactors, which reduces the risk of cell culture contamination, increases total yield and reduces the delay between seeding and harvest, thus minimizing expression product degradation,... | 1. A method for the production of a recombinant biological product, comprising:
(b) obtaining suspension-adapted cells; and (c) inoculating the suspension-adapted cells obtained in (b) into a bioreactor having a carrier providing a surface area for adherent cell culture. 2. The method according to claim 1, further comp... | We have found a counter-intuitive way to improve the commercial-scale production of recombinant biological products in adherent-cell bioreactors, which reduces the risk of cell culture contamination, increases total yield and reduces the delay between seeding and harvest, thus minimizing expression product degradation,... | 1,600 |
144 | 144 | 14,235,759 | 1,639 | The present invention relates to a method for the assembly and cloning of polynucleotides comprising highly similar polynucleotidic modules, that is highly versatile, does not require intermediate amplification step and can be easily automated for high throughput production of customized polynucleotidic modules. | 1) A method of generating and assembling polynucleotides comprising arrays of at least two highly similar polynucleotidic modules comprising the steps of:
a) generating at least one polynucleotidic building block comprising at least:
one polynucleotidic module;
a single cleavage site for a first restriction enzyme A, p... | The present invention relates to a method for the assembly and cloning of polynucleotides comprising highly similar polynucleotidic modules, that is highly versatile, does not require intermediate amplification step and can be easily automated for high throughput production of customized polynucleotidic modules.1) A me... | 1,600 |
145 | 145 | 14,651,705 | 1,631 | The present invention relates to a method and apparatus for simulating blood flow through a cardiovascular structure, e.g. a blood cavity such as the left ventricle outflow tract, the aortic root including the AV, plus ascending aorta, a ventricle volume, the aorta or any other cavity where blood flows through, under p... | 1. An apparatus for simulating blood flow through a cardiovascular structure close to the heart of a patient, said apparatus comprising:
an estimation circuit for estimating a cardiac ejection output per heart stroke based on a volume of at least one heart chamber of said patient in different filling states at two or m... | The present invention relates to a method and apparatus for simulating blood flow through a cardiovascular structure, e.g. a blood cavity such as the left ventricle outflow tract, the aortic root including the AV, plus ascending aorta, a ventricle volume, the aorta or any other cavity where blood flows through, under p... | 1,600 |
146 | 146 | 14,054,651 | 1,618 | In certain embodiments, the invention relates to systems and methods for in vivo tomographic imaging of fluorescent probes and/or bioluminescent reporters, wherein a fluorescent probe and a bioluminescent reporter are spatially co-localized (e.g., located at distances equivalent to or smaller than the scattering mean f... | 1. A method for imaging a target region of a diffuse object, the method comprising:
(a) administering a bioluminescent substrate and/or chemiluminescent substrate to the object; (b) detecting bioluminescent and/or chemiluminescent light emitted from the object by a bioluminescent reporter in the target region of the ob... | In certain embodiments, the invention relates to systems and methods for in vivo tomographic imaging of fluorescent probes and/or bioluminescent reporters, wherein a fluorescent probe and a bioluminescent reporter are spatially co-localized (e.g., located at distances equivalent to or smaller than the scattering mean f... | 1,600 |
147 | 147 | 14,649,557 | 1,617 | Disclosed are oral care compositions comprising an orally acceptable vehicle, a basic amino acid in free or salt form, particles of precipitated calcium carbonate, a source of zinc ions, and a surfactant system selected from at least one of a poloxamer nonionic surfactant and a betaine zwitterionic surfactant or a mixt... | 1. An oral care composition comprising an orally acceptable vehicle, a basic amino acid in free or salt form, calcium carbonate, a source of zinc ions, and at least one surfactant selected from a nonionic block copolymer surfactant and a betaine zwitterionic surfactant or a mixture thereof. 2. The oral care composition... | Disclosed are oral care compositions comprising an orally acceptable vehicle, a basic amino acid in free or salt form, particles of precipitated calcium carbonate, a source of zinc ions, and a surfactant system selected from at least one of a poloxamer nonionic surfactant and a betaine zwitterionic surfactant or a mixt... | 1,600 |
148 | 148 | 13,457,049 | 1,653 | Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole wh... | 1. A method of monitoring a patient with C. Difficile disease, the method comprising:
obtaining a first fecal sample from a patient at a first time; obtaining a second fecal sample from the same patient at a second time later than the first time; comparing a first amount of one or more of lactoferrin or calprotectin in... | Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole wh... | 1,600 |
149 | 149 | 14,312,763 | 1,613 | The present invention provides an oral care composition for encouraging proper tooth cleaning, containing particulate materials which can be breakable under a brushing action with a brushing force from 0.1N to 5N. The particulate materials can have a particle size distribution characterized by (1) a change ratio of mea... | 1. An oral care composition, comprising particulate materials which are breakable under a brushing action with a brushing force from 0.1N to 5N, wherein the particulate materials have a particle size distribution characterized by
(1) a change ratio of mean particle size before and after the brushing action is at least ... | The present invention provides an oral care composition for encouraging proper tooth cleaning, containing particulate materials which can be breakable under a brushing action with a brushing force from 0.1N to 5N. The particulate materials can have a particle size distribution characterized by (1) a change ratio of mea... | 1,600 |
150 | 150 | 15,279,866 | 1,628 | Compositions containing luteolin, quercetin, and kaempferol are provided. The compositions are useful killing cancer cells and treating cancer. Exemplary cancers that can be treated include, but are not limited to prostate cancer and head and neck cancer. | 1. A composition comprising luteolin, quercetin and kaempferol at a molar ratio of 1:1:2. 2. The composition of claim 1, further comprising a pharmaceutically acceptable excipient. 3. The composition of claim 1 formulated for oral administration. 4. The composition of claim 1 formulated for parenteral administration. 5... | Compositions containing luteolin, quercetin, and kaempferol are provided. The compositions are useful killing cancer cells and treating cancer. Exemplary cancers that can be treated include, but are not limited to prostate cancer and head and neck cancer.1. A composition comprising luteolin, quercetin and kaempferol at... | 1,600 |
151 | 151 | 16,276,331 | 1,629 | The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the... | 1. A method for the treatment or prophylaxis of a central nervous system disorder, comprising administering to a patient in need thereof a compound of a Formula
wherein:
X is —NH— or —N(CH3)—;
L is selected from O, NH, NRa, and S;
Z is —CH(O—R1)—, —O— or —C(O)—;
R1 is H, —C(O)—C1-21 alkyl (e.g., —C(O)—C1-5alk... | The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the... | 1,600 |
152 | 152 | 11,801,990 | 1,634 | The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary rea... | 1. A method comprising:
a) providing a ligation substrate comprising:
i) a target sequence comprising a first target domain and a second target domain;
ii) a first ligation probe comprising:
1) a first probe domain substantially complementary to said first target domain; and
2) a 5′-ligation moiety; and
iii) a second ... | The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary rea... | 1,600 |
153 | 153 | 14,216,705 | 1,642 | In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc dom... | 1. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first heavy chain constant domain comprising a first variant Fc domain; and
ii) a first antigen binding domain; and
b) a second monomer comprising:
i) a second heavy chain constant domain comprising a second variant Fc domain; and
ii) a second... | In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc dom... | 1,600 |
154 | 154 | 14,155,334 | 1,642 | The invention provides novel heterodimeric proteins including heterodimeric antibodies. | 1. (canceled) 2. A composition comprising an anti-CD3 variable region having a sequence comprising a vhCDR1 having the sequence T-Y-A-M-Xaa1, wherein Xaa1 is N, S or H (SEQ ID NO:435), a vhCDR2 having the sequence R-I-R-S-K-Xaa1-N-Xaa2-Y-A-T-Xaa3-Y-Y-A-Xaa4-S-V-K-G, wherein Xaa1 is Y or A, Xaa2 is N or S, Xaa3 is Y or ... | The invention provides novel heterodimeric proteins including heterodimeric antibodies.1. (canceled) 2. A composition comprising an anti-CD3 variable region having a sequence comprising a vhCDR1 having the sequence T-Y-A-M-Xaa1, wherein Xaa1 is N, S or H (SEQ ID NO:435), a vhCDR2 having the sequence R-I-R-S-K-Xaa1-N-Xa... | 1,600 |
155 | 155 | 14,200,652 | 1,642 | The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In ano... | 1-33. (canceled) 34. An anti-CD3 binding domain comprising a variable heavy sequence and a variable light sequence pair selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:6; SEQ ID NO:9 and SEQ ID NO:10; SEQ ID NO:13 and SEQ ID NO:14; SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:21 and SEQ ID NO:22; SEQ ID NO:... | The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In ano... | 1,600 |
156 | 156 | 14,402,678 | 1,648 | The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at le... | 1. A composition comprising a live, attenuated or genetically modified herpesvirus, and at least two or more pharmaceutically acceptable excipients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. 2. The composition of claim 1, wherein the composition further comprises at least... | The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at le... | 1,600 |
157 | 157 | 14,774,101 | 1,611 | Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances. | 1.-15. (canceled) 16. An active ingredient combination of one or more alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances. 17. The active ingredient combination of claim 16, wherein the one or more fragrances comprise one or more of coumarin, Iraldein alpha iff, farnesol, lilial, bi... | Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances.1.-15. (canceled) 16. An active ingredient combination of one or more alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances. 17. The active ingredie... | 1,600 |
158 | 158 | 14,682,698 | 1,613 | The present invention relates to systems and methods for administering high concentrations of nitric oxide (NO) gas to a patient without the need to provide supplemental oxygen to the patient. The systems and methods can be used to administer high therapeutic amounts of NO gas, for example a gas comprising 160 ppm NO, ... | 1. A method for administering nitric oxide (NO) gas to a patient, comprising:
receiving, at a gas mixing and administration device, a controlled quantity of high concentration NO gas flow from a high concentration NO gas source; receiving, at the gas mixing and administration device, air flow from an air source into th... | The present invention relates to systems and methods for administering high concentrations of nitric oxide (NO) gas to a patient without the need to provide supplemental oxygen to the patient. The systems and methods can be used to administer high therapeutic amounts of NO gas, for example a gas comprising 160 ppm NO, ... | 1,600 |
159 | 159 | 14,359,676 | 1,615 | According to the invention a transdermal therapeutic system for administering fentanyl or an analogue thereof through the skin is provided that has a pressure-sensitive adhesive matrix layer containing a mixture of two polyisobutylenes with specific storage moduli. | 1. A transdermal therapeutic system for the administration of an active ingredient through the skin comprising or consisting of
a) a back layer, b) a pressure-sensitive adhesive matrix layer containing the active ingredient; and c) a stripping layer (release liner), wherein the active ingredient is fentanyl or an analo... | According to the invention a transdermal therapeutic system for administering fentanyl or an analogue thereof through the skin is provided that has a pressure-sensitive adhesive matrix layer containing a mixture of two polyisobutylenes with specific storage moduli.1. A transdermal therapeutic system for the administrat... | 1,600 |
160 | 160 | 15,138,277 | 1,626 | The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity. | 1-15. (canceled) 16. A salt of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide which is selected from the group consisting of from sodium, tosylate, maleate, hemi pamoate, hemi naphthalenedisulfonate, mesitylenesulfonate, hemi biphen... | The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.1-15. (canceled) 16. A salt of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide which is selected from the group co... | 1,600 |
161 | 161 | 14,936,727 | 1,617 | An implantable medical device for controlling the rate of release of a therapeutic agent is provided. The implantable medical device features at least one non-bioresorbable polymer, and/or at least one bioresorbable polymer, where the bioresorbable polymers have different degrees of hydrophilicity. Further, the implant... | 1. An implantable medical device which is capable of repairing soft tissue, and means for controlling the rate of release of a therapeutic agent contained therein comprising:
at least one non-bioresorbable polymer; a plurality of bioresorbable polymers,
wherein at least one of said plurality of bioresorbable polymers h... | An implantable medical device for controlling the rate of release of a therapeutic agent is provided. The implantable medical device features at least one non-bioresorbable polymer, and/or at least one bioresorbable polymer, where the bioresorbable polymers have different degrees of hydrophilicity. Further, the implant... | 1,600 |
162 | 162 | 14,270,931 | 1,629 | A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, and effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day. | 1. A method for the treatment of recurrent herpes labialis in a human in need thereof, which method comprises administering to said human, an effective amount of the compound 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine (famciclovir), or a pharmaceutically acceptable salt thereof for a treatment period of one da... | A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, and effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day.1. A method for the treatment of r... | 1,600 |
163 | 163 | 15,303,481 | 1,629 | This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certa... | 1. A compound of the following formula:
prodrugs, derivatives, or salts thereof wherein,
R1 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl,... | This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certa... | 1,600 |
164 | 164 | 12,665,810 | 1,632 | The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or m... | 1. A fibrin glue kit for application to a surface of a body part of a patient comprising:
(i) at least two separate components required to form a fibrin glue, the at least one separated component comprises fibrinogen, and the at least second separated component comprises a proteolytic enzyme which is capable of forming... | The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or m... | 1,600 |
165 | 165 | 15,682,723 | 1,648 | A method for a pre-symptomatic diagnosis of a viral illness includes obtaining a biological sample with a peripheral blood mononuclear cell from a subject. The method further includes stimulating the biological sample, where the stimulation of the biological sample includes adding to the biological sample a predetermin... | 1. A method for a pre-symptomatic diagnosis of a viral illness in a subject, the method comprising:
(a) obtaining a biological sample comprising at least one peripheral blood mononuclear cell from a subject; (b) stimulating the biological sample, wherein the stimulation of the biological sample comprises adding to the ... | A method for a pre-symptomatic diagnosis of a viral illness includes obtaining a biological sample with a peripheral blood mononuclear cell from a subject. The method further includes stimulating the biological sample, where the stimulation of the biological sample includes adding to the biological sample a predetermin... | 1,600 |
166 | 166 | 14,685,753 | 1,627 | This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epi... | 1-20. (canceled) 21. A method for the treatment of epileptic seizures, which comprises administering to a subject in need thereof a therapeutically effective amount of the phytocannabinoid CBDV, wherein the CBDV is in the form of a botanical drug substance. 22. The method of claim 21, wherein the type of epileptic seiz... | This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epi... | 1,600 |
167 | 167 | 15,264,551 | 1,633 | Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent... | 1.-38. (canceled) 39. A method of treating a subject with ovarian cancer, comprising administering to a subject with ovarian cancer a pharmaceutically effective amount of a composition comprising:
(a) a chitosan; and (b) a nucleic acid component comprising a nucleic acid that inhibits the expression of a gene that enco... | Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent... | 1,600 |
168 | 168 | 14,487,425 | 1,631 | The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for t... | 1.-28. (canceled) 29. A method for producing a stabilized mRNA comprising synthesizing an mRNA encoding a native polypeptide sequence, wherein the mRNA encoding the polypeptide comprises a nucleic acid sequence that has an increased GuanineCytosine (G/C) content relative to the native nucleic acid sequence encoding the... | The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for t... | 1,600 |
169 | 169 | 14,510,203 | 1,644 | Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments. | 1. An isolated monoclonal antibody, wherein the antibody comprises:
(a) a first VH CDR having the sequence of VH CDR1 of 46A9BO (SEQ ID NO: 7), 9F8BO (SEQ ID NO: 21), or Z14A7 (SEQ ID NO: 13); (b) a second VH CDR having the sequence of VH CDR2 of 46A9BO (SEQ ID NO: 8), 9F8BO (SEQ ID NO: 22), or Z14A7 (SEQ ID NO: 14); (... | Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.1. An isolated monoclonal antibody, wherein the antibody comprises:
(a) a first VH CDR ha... | 1,600 |
170 | 170 | 14,053,991 | 1,644 | A methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules, is disclosed. These antibodies may be utilized in therapeutic methods of mediating cell lysis. | 1. A method of directly mediating lysis of tumorigenic cells expressing at least one specific peptide/MHC complex on a surface thereof, wherein the specific peptide of the at least one specific peptide/MHC complex is associated with a tumorigenic state, the method comprising the steps of:
contacting tumorigenic cells e... | A methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules, is disclosed. These antibodies may be utilized in therapeutic methods of mediating cell lysis.1. A method of directly mediating ... | 1,600 |
171 | 171 | 14,030,563 | 1,612 | The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In ... | 1. A method of preparing a targeted active agent cationic liposome complex, comprising:
(a) preparing a lipid solution comprising one or more cationic lipids in ethanol; (b) preparing a solution of an active agent selected from temozolomide, melphalan and atropine; (c) mixing the lipid solution with the solution of act... | The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In ... | 1,600 |
172 | 172 | 15,234,712 | 1,633 | A method of making hydrolyzed marine Type II collagen includes the mixing of marine cartilage, water, an enzyme and a protease enzyme for an extended period of time. Once mixed, the mixture is heated for a period of time at 150° F. Once heated, the enzymes are deactivated, the bone sediment separated, and the fat remov... | 1. A method of making hydrolyzed marine Type I collagen, comprising the steps of:
combining water, marine skin, and sodium hydroxide to form a mixture in a tank; mixing the tank for approximately 40 minutes; rinsing the mixture; adding water and sulfuric acid to the tank and mixing for approximately 40 minutes; drainin... | A method of making hydrolyzed marine Type II collagen includes the mixing of marine cartilage, water, an enzyme and a protease enzyme for an extended period of time. Once mixed, the mixture is heated for a period of time at 150° F. Once heated, the enzymes are deactivated, the bone sediment separated, and the fat remov... | 1,600 |
173 | 173 | 14,300,453 | 1,637 | Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by... | 1. A method for nucleic acid sequencing, comprising:
(a) providing a chip comprising a plurality of individually addressable nanopores, an individually addressable nanopore of said plurality of individually addressable nanopores containing at least one nanopore formed in a membrane disposed adjacent to an electrode, wh... | Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by... | 1,600 |
174 | 174 | 14,945,865 | 1,615 | The present invention generally relates to liquid compositions and methods for treating oral inflammation by administering a liquid composition to the oral cavity. The liquid composition is prepared from a powder containing calcium glycerophosphate, one or more sodium phosphate salts, sodium chloride, and optionally so... | 1. A powder adapted for producing a liquid composition for preventing or treating oral injury, oral inflammation, oral pain, chronic hyposalivation or complications therefrom, the powder comprising:
calcium glycerophosphate or calcium lactate gluconate; a sodium phosphate; and sodium chloride. 2. The powder of claim 1,... | The present invention generally relates to liquid compositions and methods for treating oral inflammation by administering a liquid composition to the oral cavity. The liquid composition is prepared from a powder containing calcium glycerophosphate, one or more sodium phosphate salts, sodium chloride, and optionally so... | 1,600 |
175 | 175 | 12,311,953 | 1,629 | The sagging problem in the manufacture of thick walled pipes is solved using a polyethylene molding composition having a multimodal molecular mass distribution and comprising from 45 to 55% by weight of a first low molecular weight ethylene homopolymer A, from 20 to 40% by weight of a second high molecular weight copol... | 1. A polyethylene molding composition having a multimodal molecular mass distribution for producing pipes, which comprises from 45 to 55% by weight of a first ethylene homopolymer A, from 20 to 40% by weight of a second copolymer B comprising ethylene and another olefin having from 4 to 8 carbon atoms and from 15 to 30... | The sagging problem in the manufacture of thick walled pipes is solved using a polyethylene molding composition having a multimodal molecular mass distribution and comprising from 45 to 55% by weight of a first low molecular weight ethylene homopolymer A, from 20 to 40% by weight of a second high molecular weight copol... | 1,600 |
176 | 176 | 15,287,365 | 1,644 | TIM1 antagonists reduce GVHD by symptom score and show statistically significant improved survival. | 1. A method for treating a graft versus host disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an antagonist of TIM-1. 2. The method of claim 1, wherein the antagonist is an antibody. 3. The method of claim 2, wherein the graft versus host disease is se... | TIM1 antagonists reduce GVHD by symptom score and show statistically significant improved survival.1. A method for treating a graft versus host disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an antagonist of TIM-1. 2. The method of claim 1, wherein t... | 1,600 |
177 | 177 | 14,900,907 | 1,613 | Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome. | 1. A method of treating a cognitive deficit in a subject having Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors to a subject having the cognitive deficit and Noonan syndrome. 2-3. (canceled) 4. The method of claim 1, wherein the one ... | Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome.1. A method of treating a cognitive deficit in a subject having Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors t... | 1,600 |
178 | 178 | 12,044,293 | 1,653 | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1-72. (canceled) 73. A method of removing contaminants from soil, comprising:
providing an on-site system for growing of microbes at the location of the contaminated soil; depositing inoculum, nutrient, and water into the on-site system; growing the inoculum in the on-site system to provide a treatment batch comprising... | The present invention relates to apparatus, methods, and applications for treating wastewater, and more particularly to biological processes for removing pollutants from wastewater. This invention further relates to apparatus and methods for growing microbes on-site at a wastewater treatment facility, and for economica... | 1,600 |
179 | 179 | 14,931,601 | 1,663 | The invention provides Tagetes patula ray florets comprising cyanidin-3-rutinoside, cyanidin-3-glucoside, petunidin-3-glucoside, and cyanidin in the lower epidermal layers. The invention also provides Tagetes plants comprising a mutant prdr1-1 allele and methods for producing a plant produced by crossing such plant... | 1. A Tagetes patula ray floret comprising cyanidin-3-rutinoside, cyanidin-3-glucoside, petunidin-3-glucoside, and cyanidin in the lower epidermal layers of the ray floret. 2. The ray floret of claim 1, further comprising a prdr1-1 allele. 3. The ray floret of claim 2, wherein said prdr1-1 allele confers a red color in ... | The invention provides Tagetes patula ray florets comprising cyanidin-3-rutinoside, cyanidin-3-glucoside, petunidin-3-glucoside, and cyanidin in the lower epidermal layers. The invention also provides Tagetes plants comprising a mutant prdr1-1 allele and methods for producing a plant produced by crossing such plant... | 1,600 |
180 | 180 | 15,028,644 | 1,634 | The present invention relates to a method for the detection of a specific nucleic acid. Specifically, the invention provides a method and kits for detecting the presence of a specific nucleic acid using engineered DNA-binding domains such as Transcription Activator Like-Effector (TALE) domain or modular base-per-base b... | 1. A method of detecting a nucleic acid sequence of interest comprising:
(a) Providing nucleic acids which can comprise the nucleic acid sequence of interest; (b) Providing at least one DNA binding domain capable of binding said nucleic acid sequence of interest; (c) Contacting said nucleic acids with said DNA binding ... | The present invention relates to a method for the detection of a specific nucleic acid. Specifically, the invention provides a method and kits for detecting the presence of a specific nucleic acid using engineered DNA-binding domains such as Transcription Activator Like-Effector (TALE) domain or modular base-per-base b... | 1,600 |
181 | 181 | 14,982,395 | 1,615 | Described are transdermal drug delivery systems for the transdermal administration of agomelatine. Methods of making and using such systems also are described. | 1. A transdermal drug delivery system for the transdermal delivery of agomelatine in the form of a flexible, finite system, comprising a composition comprising agomelatine and an enhancer. 2. The transdermal drug delivery system of claim 1, wherein the enhancer is selected from the group consisting of isopropanol and e... | Described are transdermal drug delivery systems for the transdermal administration of agomelatine. Methods of making and using such systems also are described.1. A transdermal drug delivery system for the transdermal delivery of agomelatine in the form of a flexible, finite system, comprising a composition comprising a... | 1,600 |
182 | 182 | 14,648,187 | 1,612 | Described herein is an oral care composition comprising an orally acceptable vehicle, a fluoride ion and a buffer having a pKa of less than 7.0 wherein the pH of the oral composition is greater than 3.5 and less than 5.0, and wherein the oral composition has an acid number greater than 4.5. | 1. An oral care composition comprising
an orally acceptable vehicle, a fluoride ion and a buffer having a pKa of less than 7.0 wherein the buffer comprises an aqueous solution of an acid and a salt of the acid, and wherein the ratio of acid:salt is between 2:1 and 1:2, wherein the pH of the oral composition is greater ... | Described herein is an oral care composition comprising an orally acceptable vehicle, a fluoride ion and a buffer having a pKa of less than 7.0 wherein the pH of the oral composition is greater than 3.5 and less than 5.0, and wherein the oral composition has an acid number greater than 4.5.1. An oral care composition c... | 1,600 |
183 | 183 | 14,863,503 | 1,634 | Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an ... | 1-11. (canceled) 12. A method comprising a genotypic analysis of a panel of genes to identify a plurality of alleles comprising:
(a) allele G of gene DRD1; (b) allele A1 of gene DRD2; (c) allele C of gene DRD3; (d) allele C of gene DRD4; (e) allele 9R of gene DAT1; (f) allele 7-11R of gene DRD4; (g) allele S or L of ge... | Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an ... | 1,600 |
184 | 184 | 15,052,825 | 1,634 | A nutritional plan based on a person's individual genetic APO E genotype, which has been shown to be the number one gene affecting diet, cholesterol, heart disease, vascular dementia, Alzheimer's disease, and chronic illness, possibly autism, Parkinson's disease, and other neurological diseases, and that focuses on the... | 1.-23. (canceled) 24. A method for creating and optimizing a nutritional and fitness regime, comprising:
performing a body composition bio-impedance test on an individual to determine the individual's caloric needs for activities of daily living for two basic activity levels, said activity levels comprising both a norm... | A nutritional plan based on a person's individual genetic APO E genotype, which has been shown to be the number one gene affecting diet, cholesterol, heart disease, vascular dementia, Alzheimer's disease, and chronic illness, possibly autism, Parkinson's disease, and other neurological diseases, and that focuses on the... | 1,600 |
185 | 185 | 14,897,616 | 1,662 | The present invention relates to methods of producing a food or malt-based beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with very low levels of hordeins. Also provided are barley plants which pro... | 1. A method of producing a food or malt-based beverage ingredient, or a food or a malt-based beverage, the method comprising (i) processing barley grain to produce malt, wort, flour or wholemeal, and/or (ii) mixing barley grain, or malt, wort, flour or wholemeal produced from said grain, with at least one other food or... | The present invention relates to methods of producing a food or malt-based beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with very low levels of hordeins. Also provided are barley plants which pro... | 1,600 |
186 | 186 | 14,694,122 | 1,658 | The invention relates to pharmaceutical compositions and methods for treating inner ear disorders. In particular, the invention provides a method for treating and/or preventing acute inner ear tinnitus in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-t... | 1. A method of ameliorating or reducing the occurrence of acute inner ear tinnitus induced by a cochlear insult in a human in need thereof comprising administering to the human a pharmaceutical composition comprising a therapeutically effective amount of a peptide inhibitor of c-Jun N-terminal kinase (JNK) or a pharmac... | The invention relates to pharmaceutical compositions and methods for treating inner ear disorders. In particular, the invention provides a method for treating and/or preventing acute inner ear tinnitus in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-t... | 1,600 |
187 | 187 | 15,408,339 | 1,633 | The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a cationic or polycationic compound, and b) at least one free mRNA, encoding at least one therapeutically active protein, antigen, allergen and/or antibo... | 1. A method of stimulating an immune response in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising
(a) an adjuvant component, comprising or consisting of at least one RNA, complexed with protamine; and (b) at least one free mRNA, encoding at least one anti... | The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a cationic or polycationic compound, and b) at least one free mRNA, encoding at least one therapeutically active protein, antigen, allergen and/or antibo... | 1,600 |
188 | 188 | 13,623,626 | 1,627 | The present invention is directed to a water treatment composition, containing 50-99.9 wt. % of particulate halogen-releasing compound; and 0.1-10 wt. % of granular fluoropolymer, wherein all weight percentages are based on the total weight of the composition. The present invention is also directed to a water treatment... | 1. A water treatment composition, comprising:
50-99.9 wt. % of a particulate halogen-releasing compound, said halogen-releasing compound comprising a compound selected from the group consisting of chlorinated isocyanuric acids, chlorine containing hydantoins, bromine-containing hydantoins and mixtures thereof; and 0.1-... | The present invention is directed to a water treatment composition, containing 50-99.9 wt. % of particulate halogen-releasing compound; and 0.1-10 wt. % of granular fluoropolymer, wherein all weight percentages are based on the total weight of the composition. The present invention is also directed to a water treatment... | 1,600 |
189 | 189 | 13,250,086 | 1,651 | Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound he... | 1. A method of preparing a growth factor enriched construct, comprising:
collecting a blood sample comprising unaggregated fibrin; mixing the blood sample in a container with a coagulation activator to initiate aggregation of the fibrin; exposing the blood mixture to a separation force that separates the blood mixture ... | Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound he... | 1,600 |
190 | 190 | 10,986,123 | 1,615 | A fragrance sampler is provided which is made from a bottom ply and a top ply of material and an applicator. A cosmetic sample, such as a wet fragrance, is deposited on the bottom ply. An absorbent applicator attaches to the top ply. The applicator collects a portion from the sample and then applies the portion for tes... | 1. A sampler for inserting into printed matter such as a magazine or a mass mailing, the sampler including:
a bottom ply having a top surface and a bottom surface; a well formed in said bottom ply to receive a cosmetic sample; a top ply having a top surface and a bottom surface; one or more walls formed in at least... | A fragrance sampler is provided which is made from a bottom ply and a top ply of material and an applicator. A cosmetic sample, such as a wet fragrance, is deposited on the bottom ply. An absorbent applicator attaches to the top ply. The applicator collects a portion from the sample and then applies the portion for tes... | 1,600 |
191 | 191 | 15,398,207 | 1,613 | An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slu... | 1. A composition comprising:
about 90% to about 99% microcrystalline cellulose; and about 1% to about 10% at least one binder; wherein the microcrystalline cellulose and binder are indistinguishable when viewed with a SEM, thereby forming substantially homogeneous-particles. 2. The composition of claim 1 wherein the co... | An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slu... | 1,600 |
192 | 192 | 13,340,405 | 1,611 | A biologic-adsorbent, e.g., protein-adsorbent, material is prepared by forming a polymeric substrate into structures having high surface area topography whose biologic adsorbing properties can be controlled. Biologic adsorption by these structures of optimized high surface area topography is increased by mild treating ... | 1. A biologic adsorbent structure comprising a polymeric substrate having a substantially fixed topography, said substantially fixed topography comprising substructures having dimensions ranging from about 100 nanometers to about 50 microns, said substructures formed by contact with a shaped surface for imparting incre... | A biologic-adsorbent, e.g., protein-adsorbent, material is prepared by forming a polymeric substrate into structures having high surface area topography whose biologic adsorbing properties can be controlled. Biologic adsorption by these structures of optimized high surface area topography is increased by mild treating ... | 1,600 |
193 | 193 | 11,638,450 | 1,616 | The present invention relates to compositions and methods for disease control in plants. The compositions for use in the methods of the invention include glyphosate as the active compound. In addition, methods and compositions are disclosed to prevent and treat pest infection in glyphosate tolerant plants. | 1. A method of controlling a fungal or fungal-like pathogen induced disease in a glyphosate tolerant onion plant comprising,
identifying an onion plant in need of disease control; and contacting said onion plant with an effective amount of a composition having glyphosate, whereby said disease of said onion plant is c... | The present invention relates to compositions and methods for disease control in plants. The compositions for use in the methods of the invention include glyphosate as the active compound. In addition, methods and compositions are disclosed to prevent and treat pest infection in glyphosate tolerant plants.1. A method o... | 1,600 |
194 | 194 | 12,781,981 | 1,626 | The present invention relates to new types of metal complexes. Such compounds can be used as active components (=functional materials) in a series of different types of applications which can be classed within the electronics industry in the widest sense.
The inventive compounds are described by the structure 1 a... | 1.-30. (canceled) 31. A compound of the following formula
[V-L3]M wherein M is a metal selected from the group consisting of Al, Ga, In, Tl, P, As, Sb, Bi, Sc, Y, La, V, Nb, Ta, Cr, Mo, W, Fe, Ru, Os, Co, Rh, Ir, Cu, Au, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu; V is a bridging unit, which contains from 1 to... | The present invention relates to new types of metal complexes. Such compounds can be used as active components (=functional materials) in a series of different types of applications which can be classed within the electronics industry in the widest sense.
The inventive compounds are described by the structure 1 a... | 1,600 |
195 | 195 | 14,493,475 | 1,631 | A person-support structure includes a control system, an input configured to communicate a first input signal to the control system, and a sensor configured to sense a physiological characteristic of a person supported on the person-support structure. The sensor communicates a second input signal corresponding to the p... | 1. A method of predicting the onset of an adverse condition, the method comprising
receiving a first input signal from an input, receiving a second input signal corresponding to a physiological characteristic of a person supported on a person-support structure, calculating a condition score as a function of the first i... | A person-support structure includes a control system, an input configured to communicate a first input signal to the control system, and a sensor configured to sense a physiological characteristic of a person supported on the person-support structure. The sensor communicates a second input signal corresponding to the p... | 1,600 |
196 | 196 | 14,486,346 | 1,639 | Provided herein is a method comprising: (a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence and can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby spatially-separatin... | 1. A method comprising:
(a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence and can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby spatially-separating the different ... | Provided herein is a method comprising: (a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence and can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby spatially-separatin... | 1,600 |
197 | 197 | 15,027,910 | 1,611 | A transdermal patch suitable for releasing a stimulant such as caffeine for an extended time period utilizes a pressure sensitive acrylic adhesive matrix constituted by an acrylic adhesive having hydroxy groups and an acrylic adhesive without hydroxy, groups, preferably in a respective weight ratio of about 2 to about ... | 1. A transdermal patch comprising
a backing layer; a pressure-sensitive acrylic adhesive matrix on the backing layer; and a xanthine composition comprising guarana seed extract and caffeine in said matrix; and a protective release sheet over the pressure-sensitive acrylic adhesive matrix; the pressure-sensitive acrylic... | A transdermal patch suitable for releasing a stimulant such as caffeine for an extended time period utilizes a pressure sensitive acrylic adhesive matrix constituted by an acrylic adhesive having hydroxy groups and an acrylic adhesive without hydroxy, groups, preferably in a respective weight ratio of about 2 to about ... | 1,600 |
198 | 198 | 14,774,102 | 1,615 | Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV-filter substances. | 1.-15. (canceled) 16. An active ingredient combination of one or more alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV-filter substances. 17. The active ingredient combination of claim 16, wherein the one or more UV-filter substances comprise one or more of butylmethoxydibenzoylmethane... | Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV-filter substances.1.-15. (canceled) 16. An active ingredient combination of one or more alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV-filter substances.... | 1,600 |
199 | 199 | 14,381,896 | 1,627 | The present invention relates to the application of modafinil in cocaine addiction. The modafinil used is its dextro-rotatory enantiomer (S modafinil), having a release time of less than 1 hour and wakening effect of less than 4 hours. It is absorbed orally as a pharmaceutical composition, each unit dose including from... | 1. An application of modafinil in the substitution treatment of cocaine addicts, consisting of using a pharmaceutical composition in which said modafinil is in the form of its dextro-rotary enantiomer, S modafinil, wherein the dose of S modafinil absorbed by the patient is from 50 to 100 mg per unit dose. 2. The applic... | The present invention relates to the application of modafinil in cocaine addiction. The modafinil used is its dextro-rotatory enantiomer (S modafinil), having a release time of less than 1 hour and wakening effect of less than 4 hours. It is absorbed orally as a pharmaceutical composition, each unit dose including from... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.